Skip to main content
Premium Trial:

Request an Annual Quote

MAUI microfluidic hybridization system, BioArray Software Environment (BASE)

Premium

BioMicro of Salt Lake City, Utah, has commercially launched its MAUI microfluidic hybridization system for microarrays. BioMicro’s arrays apply its patented technique of controlling fluid through microchannels using passive valves. Each MAUI chip is disposable, can fit atop most standard microscope slide arrays, and costs about $50, the company said. The current platform is manual, but BioMicro intends to develop an automated version for the manipulation of multiple samples of reagents.

Lao Saal and colleagues from the department of oncology in Sweden’s Lund University have released a new open source microarray database, BioArray Software Environment (BASE). BASE is compliant with the Minimal Information About a Microarray Experiment (MIAME) standard, is designed to be installed in a lab or group of labs, and can be used as a web interface. The system was developed using the Linux platform, and only requires that the user have his or her own server and a PC. Information about BASE is available at the department’s website, http://base.thep.lu.se.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.